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Abstract
Clostridium difﬁcile infection (CDI) is increasing problem in health-
care, associated with high incidence, mortality, and costs in hospi-
talized patients. Dramatic increases in the incidence and severity of 
healthcare-associated C. difﬁcile infection have occurred since the last 
decade, including elderly population, young adults, pregnant females, 
infants and children. C. difﬁcile infections are mainly linked to the 
prolonged use of wide-spectrum antibiotics that disrupt the intestinal 
microbiota equilibrium. Toxigenic strains of C. difﬁcile commonly pro-
duce two clostridial toxins, toxins A (TcdA) and B (TcdB), which are 
responsible for disease symptoms. Few strains of C. difﬁcile may also 
produce another more powerful binary toxin associated with high 
fatality. The clinical manifestations of infection with toxin-producing 
strains of C. difﬁcile range from symptomless carriage to mild or mod-
erate watery-bloody diarrhea, and few percentage developed fulmi-
nant and sometimes fatal pseudomembranous colitis. Complications 
that have been associated with CDI include dehydration, electrolyte 
disturbances, toxic megacolon, bowel perforation, hypotension, renal 
failure, systemic inﬂammatory response syndrome, sepsis, and death. 
The most important step in treating CDI is immediately discontinuing 
use of offending antimicrobial drug. Both metronidazole and vanco-
mycin are equally effective for the treatment of mild CDI, but vanco-
mycin is superior for treating patients with severe C. difﬁcile disease. 
Recently, fidaxomicin proved to be superior to other drugs in treat-
ment of patients who are at high risk for CDI relapse. 
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The Genus Clostridium was first described in 
1880, consists of a large number of species with 
a wide range of biochemical and physiological 
features. Clostridia are gram positive spore forming 
bacilli and obligatory anaerobic. Clostridium difﬁcile 
is present in different rates as part of the indigenous 
human gut ﬂora. It has also been isolated from 
diverse natural sources including soils, sand, and the 
intestinal tracts of animals. The spectrum of disease 
associated with C. difﬁcile ranges from asymptomatic 
carriage to life-threatening pseudomembranous 
colitis. Hospitalized patients may frequently develop 
antibiotic associated colitis or antibiotic associated 
diarrhea after short or long stay in hospitals [1-2]. 
In recent years, C. difﬁcile infection (CDI) become 
an increasing heath problem in elderly hospitalized 
patients and as community-acquired infection, 
and which can be associated with high incidence, 
mortality, and healthcare costs [3,4]. 
Clostridium difficile disease
The clinical and pathological features of C. 
difﬁcile disease (CDD) indicate that it is difficult to 
distinguish from other similar intestinal diseases, 
including ulcerative colitis, chronic inﬂammatory 
bowel disease, and Crohn’s disease [5]. The clinical 
manifestations of infection with toxin-producing 
strains of C. difﬁcile range from symptomless 
carriage, to mild or moderate diarrhea, fulminant 
and sometimes fatal pseudomembranous colitis. 
C. difﬁcile diarrhea may be associated with the 
passage of mucus or occult blood in the stool. Fever, 
cramping, abdominal discomfort, and a peripheral 
leukocytosis are also common but found in fewer 
than half of patients. Extra intestinal manifestations, 
such as arthritis or bacteremia are very rare [5]. 
The onset of symptoms after antibiotic treatment 
in adults has been ranged between 1 day to 6 weeks 
and longer [6], while the incubation period from 
antibiotic exposure to develop symptomatic CDI in 
children is shorter and between two to three days [7]. 
Almost all patients with C. difﬁcile associated disease 
showed brown or clear watery diarrhea, but less than 
50% have bloody diarrhea [5, 8-9]. The majority of 
patients (85%) with peudomembranous colitis appear 
to have mucus in their faeces, and their temperature is 
elevated and exceeds 38°C. Additionally, leukocytosis 
is a common clinical feature in the severely ill patient, 
and complications include dehydration, electrolyte 
disturbances, toxic megacolon, bowel perforation, 
hypotension, renal failure, systemic inﬂammatory 
response syndrome, sepsis, and death [5]. Complications 
are more likely to develop among neutropenic children 
with haematological malignancies or those treated with 
hematopoietic stem cell transplantation, infants with 
Hirschsprung’s disease and patients with inﬂammatory 
bowel disease [7]. 
Clostridium difﬁcile diseases are mainly linked to 
the use of wide-spectrum antibiotics that disrupt 
the intestinal microbiota equilibrium. This allows 
C. difﬁcile to multiply and colonize the gut [10]. 
Intestinal colonization is an essential step in the 
pathogenic process of C. difﬁcile and its disease 
depends on the loss of the commensal microbiota 
barrier effect following antibiotic treatment as 
observed in early infancy in infants [10]. 
According to guidelines from the Infectious 
Diseases Society of America (IDSA) and the Society 
for Healthcare Epidemiology of America (SHEA) 
a case definition of CDI includes the following 
findings : (a) the presence of diarrhea, defined as 
passage of 3 or more unformed stools in 24 or 
fewer consecutive hours1-8, (b) a stool test result 
positive for the presence of toxigenic C. difﬁcile 
or its toxins, (c) a colonoscopic or histopathologic 
findings demonstrating pseudomembranous colitis. 
The same criteria should use to diagnose recurrent 
CDI. A history of treatment with antimicrobial or 
antineoplastic agents within the previous 2-month 
is present in the majority of patients [5]. 
CDI is defined as hospital-acquired if symptom 
onset occurred after 48 hours of admission, and 
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less than 4 weeks after discharge from a healthcare 
facility, while CDI was defined as community-acquired 
if onset of symptoms occurred in the community or 
within 48 hours of admission to a hospital, pending 
no clinical symptoms of CDI observed over 12 weeks 
after the last discharge from a hospital [11]. Watery 
diarrhea is the most frequent manifestation of CDI 
in children due to release C. difﬁcile toxins [7]. 
CDI may be considered if an infant with antibiotic 
exposure has persistent diarrhea and associated with 
abdominal findings that persist despite supportive 
care and absence of typical viral and bacterial 
pathogens. Additionally, if endoscopy or surgery 
detects pseudomembranous colitis [12]. 
Transmission of C. difficile
The organism is acquired through ingestion 
of spores usually transmitted from other patients 
through the hands of health care personnel or the 
environment. The spores resist the acidity of the 
stomach and germinate into the vegetative form in 
the small intestine [9]. The spores of C. difﬁcile persist 
in a dormant state and are difficult to eradicate 
from the hospital environment and elsewhere [13]. 
The primary mode of C. difﬁcile transmission is 
person-to-person spread through the fecal-oral 
route, principally within hospitalized patients. The 
hands of healthcare workers, are important source 
for transmission the organism during non-outbreak 
periods [5]. The major reservoirs for C. difﬁcile in 
the hospital setting are patients with CDAD or 
asymptomatic carriers of C. difﬁcile who heavily 
contaminate the hospital environment [14]. 
Asymptomatic carriage of  
C. difficile
Asymptomatic carriage was defined as a positive 
stool culture or cytotoxin test and the absence of 
diarrhea during hospitalization and during a 30-
day period after discharge. Epidemiological Studies 
have indicated that the prevalence of asymptomatic 
colonization with C. difﬁcile is ranged between 
7–26% among adult inpatients in acute care facilities 
and is 5-7% among elderly patients in long-term 
care facilities [5,15]. The risk of colonization increases 
at a steady rate during hospitalization, suggesting 
accumulative daily risk of exposure to C. difﬁcile 
spores in the healthcare setting [12]. Newborns and 
children in their first year of life are known to have 
some of the highest rates of colonization [5,7]. Infants 
and children are significantly more likely to carry C. 
difﬁcile asymptomatically in the gastrointestinal (GI) 
tract than adults. It is estimated that 15-63% of 
neonates, 3-33% of infants and children younger 
than two years of age, and up to 8.3% of children 
older than two years of age are asymptomatic 
carriers [7]. Infants and young children rarely develop 
symptoms, possibly because of immature surface 
intestinal receptors for C. difﬁcile, and because 
they are protected by maternal antibodies acquired 
transplacentally or in breast milk [7,16]. About 51% of 
asymptomatic patients carried toxigenic C. difﬁcile, 
of which 37% associated with an epidemic strain 
[17]. Asymptomatic patient is potentially serve as a 
reservoir for horizontal transmission of epidemic and 
non-epidemic C. difﬁcile strains to other patients, 
either by contamination of the environment or by 
contact with hands of medical personnel [18]. 
Antibiotic-associated diarrhea 
and pseudomembranous colitis
Generally mild to moderate diarrhea, sometimes 
accompanied by lower abdominal cramps is 
seen with C. difﬁcile infection. Symptoms usually 
begin during or shortly after antibiotic therapy. 
Occasionally these may be delayed for several weeks 
[19]. Patients with CDI typically present with watery 
diarrhea and bloody stools are rare. Patients can be 
also presented with symptoms of colitis, fever, lower 
THE INTERNATIONAL ARABIC JOURNAL OF ANTIMICROBIAL AGENTS
ISSN 2174-9094
2015
Vol. 5 No. 4:1 
doi: 10.3823/778
4 Received 19 January, Accepted 7, February 2016  This article is available from: www.iajaa.org / www.medbrary.com 
abdominal cramps, and fecal leukocytes [19,20]. 
C. difﬁcile toxins can be usually detected in fecal 
specimens, even though endoscopic and histologic 
features may be normal in patients with mild 
disease. The diarrhea resolves with discontinuation 
of antibiotics with 2-3 days, and the most common 
clinical manifestation of C. difﬁcile infection is 
colitis without pseudomembrane formation[19]. 
Sometimes dehydration and a low-grade fever with 
a systemic polymorphonuclear leukocytosis may 
occur. A nonspecific diffuse or patchy erythematous 
colitis without pseudomembrane may be seen under 
sigmoidoscopy [19, 20].
Pseudomembranous colitis (PMC) is the classic 
manifestation of full-blown C. difﬁcile colitis and 
is accompanied by similar, but often more severe 
symptoms than those observed in colitis. The classic 
pseudomembranes, which are raised yellow plaques 
ranging from 2-10 mm in diameter scattered over 
the colorectal mucosa. White blood cell counts of 
20,000 /mm³ or greater and hypoalbuminaemia of 
3.0 g/dl or lower may be observed in severely ill 
patients [19]. PMC lesions are nearly always limited 
to the colon. PMC became a commonly recognized 
complication of antibiotic use in the early 1950s and 
was primarily encountered by surgeons, who reported 
rates as high as 14–27% among postoperative 
patients. Staphylococcus aureus was the suspected 
pathogen, and vancomycin given orally became 
standard treatment for this condition. There are 
multiple other causes of PMC, including intestinal 
obstruction, colon cancer, leukemia, severe burns, 
shock, uremia, heavy metal poisoning, hemolytic-
uremic syndrome, Crohn disease, shigellosis, 
neonatal necrotizing enterocolitis, ischemic colitis, 
and Hirschsprung disease. However, the vast 
majority of PMC cases seen since 1978 have been 
attributed to C. difﬁcile [2,5]. Pseudomembranous 
colitis can only be diagnosed by direct visualization 
of pseudomembranes on lower gastrointestinal 
endoscopy; either by sigmoidoscopy or colonoscopy 
and by histopathologic examination. However, 
direct visualization using any of these techniques 
will detect pseudomembranes in only half of CDI 
cases that are diagnosed by combined clinical and 
laboratory tests that include both a culture positive 
for C. difﬁcile and a positive stool cytotoxin test 
result. Pseudomembranous colitis can be used as a 
marker of severe C. difﬁcile disease [2].
Fulminate colitis occurs in > 5% Patients with CDI, 
and patients are severely ill and associated with about 
50% mortality [20]. Patients with fulminant colitis 
complain of severe lower and diffuse abdominal 
pain, diarrhea, and distension and some of them may 
exhibit high fever, chills and marked leukocytosis. 
Severe protein-losing enteropathy may result in 
hypoalbuminaemia. A patient with toxic megacolon 
has a dilated colon with signs and symptoms of 
severe toxicity that include fever, chills, dehydration 
and high white blood count [19]. The timing from 
onset of any CDI symptoms to fulminant colitis varies 
widely from weeks to just a few hours [20]. 
Recurrence may result from relapse of the initial 
infecting strain or due to reinfection with a new strain 
[21]. Symptomatic recurrence of CDI after successful 
treatment causes significant morbidity and can 
prove challenging to treat effectively [22]. Reported 
recurrence rates vary from 5% to 50% and typically 
are around 20%. Recurrence risk factors included older 
age, use of provocative antibiotics after CDI diagnosis, 
concomitant receipt of antacids, hospital-acquired 
disease, and comorbid conditions, including severe 
underlying illness or poor quality of life scores. CDI 
most commonly recurs within a week after finished 
treatment, but can recur after to 6–8 weeks later. 
About 50% of apparent relapses have been identified 
as new infections with a different strain [23]. 
Nosocomial infection by  
C. difficile
Dramatic increases in the incidence and severity 
of healthcare-associated C. difﬁcile   
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infection have occurred since 2000, particularly 
in patients over age 65 [3,5]. About 20% of 
patients with negative C. difﬁcile  stool cultures 
after admission become infected during their 
hospitalization. Although asymptomatic individuals 
are capable of shedding spores of C. difﬁcile  and 
serve as a reservoir for infection hospitalized patients 
[24]. New exposure and colonization by C. difﬁcile are 
more likely causing CDI, while patients previously 
colonized with  C. difﬁcile  are more likely to remain 
asymptomatic during their hospitalization [25]. The 
rate of acquisition of CDI during hospitalization is 
proportional to the duration of hospitalization and 
can be as high as 40% after 1 month [12]. Different 
studies showed that C. difﬁcile was a major agent of 
nosocomial diarrhea in adults. The frequency of C. 
difﬁcile or toxins in stool culture prescribed at least 3 
days after patients’ admission. C. difﬁcile or toxins are 
recovered from 8–10% of nosocomial diarrhea [14-15]. 
One explanation for an increase in both the rate and 
the severity of C. difﬁcile-associated diarrhea could be 
the emergence of an epidemic strain with increased 
virulence, antimicrobial resistance or both [26]. 
Risk factors of CDI
Several important risk factors for acquiring 
CDI have been identified and are summarized 
in Table  1. Antibacterial exposure is the most 
common risk for the development of CDI. 
Generally, every antibacterial can be associated 
with the development of CDI, including ironically 
metronidazole and vancomycin. The indigenous gut 
microbiota is normally protect against colonization 
or infection with C. difﬁcile. Antibacterial can disrupt 
the competitive balance in the gut microbiota and 
promote the overgrowth of C. difﬁcile. Several 
antibacterial classes appear to increase the risk of 
CDI compared to others, including clindamycin, 
cephalosporins and ﬂuoroquinolones [1,27]. Recent 
studies showed that carbapenems place patients at 
a relatively higher risk for CDI, compared with other 
antibiotics such as first-generation cephalosporins 
or macrolides [20]. Cumulative antibiotic exposure 
via dose, use of multiple antibacterial agents, and 
increased days of antibiotic exposure all contribute to 
the risk of CDI. Alternatively, limited exposure, such 
as a single-dose antibacterial exposure for surgical 
prophylaxis also increases the risk of both C. difﬁcile 
colonization and infection. Some investigators have 
hypothesized the increased incidence of CDI in 
young, healthy peripartum women may be a result 
of exposure to antibacterial prophylaxis associated 
with Cesarean sections [1]. The second important 
risk factor is mostly observed among the elderly 
population. This is most likely due to changes in the 
intestinal microbiota, an increased use of antibiotic 
and more frequent hospitalization [3,28]. Advanced 
age has repeatedly been found to be a risk factor 
for CDI. The risk for CDI has been thought to begin 
to increase at age 65. It was reported that for each 
year of age, the risk of health care acquired CDI 
increases by 2%. The increase in risk could result in 
part from reduced immune system function with 
age, particularly of the humoral immune response 
[9,20]. The other risk factors such as gastric acid 
suppression and host related factors are restricted 
to small group of patients [1,29].
Table 1.  Patient risk factors for initial Clostridium 
difﬁcile infection [1].
Risk for Initial episode
Antibacterial therapy
Advanced age (≥65 years)
Gastric acid suppressing agents
Cancer chemotherapy and HIV infection
Enteral feeding and gastrointestinal surgery
Healthcare exposure
Impaired immune response
Underlying chronic comorbidities
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Clostridium difficile infection  
in infants and children
CDI has been reported in populations 
previously considered to be at low risk, including 
young adults, pregnant females, and children. 
Traditionally, neonates and infants were believed to 
be asymptomatic carriers of C. difﬁcile; however, 
recent studies have suggested that CDI is emerging 
as a cause of diarrhea in infants and children [11]. 
Moreover, evidence suggests that a large proportion 
of pediatric CDI cases are community-acquired 
infections and that many of these infections lack the 
traditional risk factor of exposure to antimicrobial 
drugs [29]. The high rate of intestinal colonization of 
infants with C. difﬁcile and the low rates of clinical 
disease appears to be due to the low capacity of 
the infant gut to suppress growth of C. difﬁcile [31-
32]. The prevalence of C. difﬁcile colonization in 
neonates ranges from 2% - 50% with colonization 
often occurring within the first week of life. By 
approximately 2 years of age, colonization rates are 
similar to those in adults. However, asymptomatically 
colonize infants represent a potential reservoir for 
transmission to other family members [12]. It was 
initially hypothesized that infants were colonized 
with non-toxigenic strains of C. difﬁcile, and this 
was the reason for the absence of disease. Potential 
mechanisms for disease resistant in neonates include 
relatively low numbers of the pathogen in the infant 
gut, colonization with nontoxigenic, absence of toxin 
receptors in the immature gut mucosa, and protective 
components in breast milk [16]. However, multiple 
studies have now demonstrated the presence of 
toxin-producing strains in asymptomatic neonates 
[32]. The American Academy of Pediatrics (AAP) 
Committee, recommended avoiding routine testing 
for C. difﬁcile in children younger than 1 year of 
age based on the known high rates of colonization 
and infrequent disease. They also recommended 
that testing should be limited in this age group to 
those with risk factors, as Hirschsprung disease or 
other severe motility disorders or in an outbreak 
situation [33]. Recent data have shown that 26% 
of pediatric disease that was treated due to CDI 
occurred in infants younger than one year of age 
and 5% occurred in neonates [7]. Treating infants 
with diarrhea with antibiotics directed against C. 
difﬁcile usually does not alter the course of the 
diarrhea, even if C. difﬁcile is present in the stool 
[16]. Studies have also demonstrated that mode 
of delivery by vaginal, cesarean, and instrumental 
delivery had similar yields of C. difﬁcile in stool of 
newborn babies. Furthermore, premature rupture 
of membranes (PROM), sex, and prior administration 
of antibiotics to the mother or the neonate had no 
effect on carriage rates. Longer duration of hospital 
stay of babies appears to increase the prevalence 
of the carrier state, possibly through increased 
exposure to C. difﬁcile [16].
Pathogencity and virulence 
factors of C. difficile 
The indigenous microbiota of the colon provide 
an important host defense by inhibiting colonization 
and overgrowth of C. difﬁcile and other potential 
pathogens [34]. The acid resistance of the organism 
allows its spores to pass readily through the stomach, 
enabling germination in the small bowel on exposure 
to bile acids [35]. C. difﬁcile produces a number 
of virulence factors that contribute to its virulence. 
These include adhesion, toxin release, hydrolytic 
enzyme secretion, ﬂagella, fibronectin-binding 
protein, antiphagocytic capsule and host factors, 
and all together contribute to the pathology and 
feature of infection in the human host [14,36,37]. 
Toxigenic strains of C. difﬁcile commonly produce 
two large clostridial toxins, toxins A (TcdA) and B 
(TcdB), to which disease symptoms are attributed. 
They are encoded by genes tcdA and tcdB. Together 
with three additional genes (tcdC, tcdD, and tcdE), 
they form the pathogenicity locus (PaLoc), of 19.6 
 This article is available from: www.iajaa.org / www.medbrary.com 
THE INTERNATIONAL ARABIC JOURNAL OF ANTIMICROBIAL AGENTS
ISSN 2174-9094
2015
Vol. 5 No. 4:1 
doi: 10.3823/778
© Under License of Creative Commons Attribution 3.0 License 7
kb, which is found only in toxinogenic strains [38]. 
Both toxins A and B induce mucosal injury and coli-
tis as observed by neutrophil infiltration, which is a 
prominent feature of CDAD. Toxin A is an entero-
toxin that causes haemorrhage and ﬂuid secretion 
in the intestines of rodents whereas toxin B is a 
cytotoxin detectable by its cytopathic effects in tis-
sue culture. Toxin A causes extensive damage to 
the epithelial lining of the intestine and acts as a 
cytotoxin resulting in disruption of the tight junc-
tions of the intestinal epithelium. Toxin A initially 
induces cell rounding which results in detachment 
of the cell from the basement membrane, followed 
by apoptosis. After toxin A has bound to the re-
ceptor initiating the damage, toxin B joins in and 
gains access to the underlying tissue. The cytotoxic 
activity of toxin B is similar to that of toxin A, but 
is 1000-fold more potent than the former [19]. The 
prevalence rates of non-toxigenic C. difﬁcile strains 
in healthy humans are ranged between 10-40% 
[15,17,38]. These strains do not produce toxins in 
vivo or in vitro and can colonize the gastrointes-
tinal tract and grow normally in culture media as 
the toxigenic strains [15,38]. Table 2 shows major 
characteristics of Clostridium difﬁcile toxins.
Some strains of C. difﬁcile also produce addi-
tive binary toxins CDT; an actin-specific adenine-
diphosphate (ADP)-ribosyltransferase known as bi-
nary toxin CDT, which was first described in 1988 
[38]. The binary toxin CDT is unrelated to the well-
characterized toxins TcdA and TcdB. It belongs to 
the group of clostridial binary toxins, which include 
the iota toxin of Clostridium perfringens type E, the 
toxin of Clostridium spiroforme, and the C2 toxin 
of Clostridium botulinum C and D [39]. The binary 
toxin CDT contains the genes of cdtA and cdtB, with 
an organization and sequences similar to the genes 
of the iota toxin of C. perfringens: the protein se-
quences of CDTa and CDTb are 81 and 84% similar, 
respectively, to the corresponding iota toxin pro-
teins. It was shown that only strains with changes in 
toxin genes tcdA and tcdB (variant strains) produce 
binary toxin [40]. Since the majority of strains iso-
lated from symptomatic patients produce only TcdA 
/ TcdB or both, and this indicates that CDT is not 
required for the virulence of C. difﬁcile, but it may 
serve as an additional virulence factor [39]. Earlier 
studies found the binary toxin was only present in 
about 6% of C. difﬁcile clinical isolates [5].. Binary 
toxin, has been detected recently in 17% to 23% 
of clinical strains, but its role in human disease has 
not been clearly defined [41]. 
Increased CDI incidence and severity have been 
attributed largely to the emergence of a new strain 
of C. difﬁcile, designated by restriction endonucle-
ase analysis type BI, North American pulsed-field 
gel electrophoresistype1 (NAP1), polymerase chain 
reaction (PCR) ribotype 027 (BI/NAP1/027) [8,26]. 
Several characteristics found in BI/NAP1/027 may 
contribute to its hypervirulence, including polymor-
phisms in an important toxin production down 
regulatory gene, tcdC; increased toxin production; 
Table 2. Comparison of Clostridium difﬁcile toxins
Characteristics Toxin A Toxin B
Molecular weight 308 kDa 279 kDa
Cytotoxin + +++
Intracellular mechanism of cytotoxity Glycosylated Rho Proteins Glycosylated Rho Proteins
Receptors
Present on enterocyte and other cell 
types
Absent on enterocyte and present on 
other cell types
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presence of the gene encoding binary toxin (ctdA 
and ctdB); high-level ﬂuoroquinolone resistance and 
polymorphisms in tcdB that could result in improved 
toxin binding [8]. This toxigenotype (NAP1/027) can 
produce 16 times more toxin A and 23 times more 
toxin B than control strains [42]. The NAP1 strain 
has entered the pediatric population at lower rates 
(10–19%) of toxigenic C. difﬁcile isolates than re-
ported for adults (>50%) [18,43]. 
Laboratory diagnosis of  
C. difficile infection
Rapid and accurate diagnosis of CDI is essential 
for improving outcomes of patients and the overall 
management of its nosocomial infection [44]. The 
diagnosis of CDI should be based on a combination 
of clinical and laboratory findings [4]. 
The medium cycloserine-cefoxitin fructose agar 
(CCFA) is the most used selective culture for recovery 
of C. difﬁcile [5]. The second commonly used C. 
difﬁcile moxalactam-norﬂoxacin agar plates (CDMN) 
is also highly selective for its isolation[45]. The 
selection of spores from feces samples by alcohol 
shock greatly diminishes almost all competing fecal 
ﬂora and enhances both the isolation and easier 
recognition of C. difﬁcile. The addition of bile salts, 
such as sodium cholate or taurocholate, to the 
culture medium is believed to enhance the recovery 
of spores by inducing the germination of spores 
from environmental samples or faeces after alcohol 
shock [46]. Optimal results require that culture 
plates be reduced in an anaerobic environment 
prior to use. The colonies are ﬂat, yellow and have 
a typical odor and ﬂuoresce with a Wood’s lamp. 
Additionally, Gram stain shows typical morphology 
of gram-positive or gram-variable bacilli [5]. There 
are several biochemical tests, cytotoxin assay and 
immunological test available to confirm the identity 
of C. difﬁcile or to detect toxin. Each test has unique 
characteristics as presented in Table 3. 
Detection of C. difficile Toxins: Toxin B (cytotoxin) 
which is produced by toxigenic strains of C. difﬁcile 
can be detected by different cell lines such as Vero, 
HEP-2 or MRC-5 monkey kidney and HeLa cell lines 
[5]. The first enzyme immunoassay (EIA) for detecting 
C. difﬁcile toxin in fecal samples was developed and 
evaluated by Yolken et al., in 1981 [47]. Commercial 
EIA tests have been introduced that either detect 
toxin A only or detect both toxins A and B. It has 
been the most widely used diagnostic test for CDI [8]. 
Detection of C. difficile Toxin by Molecular 
Methods: Several nucleic acid amplification tests 
 This article is available from: www.iajaa.org / www.medbrary.com 
Table 3. Laboratory diagnosis of Clostridium difﬁcile or its toxin in feces samples 
Test
Sensitivity 
(%)
Specificity 
(%)
Advantages Disadvantages
Stool culture & 
biochemical test
90-100 98-100 Allows strain typing 
& antibiotic susceptibility
Takes 2-5 days 
EIA toxin test for both 
A & B
65-85 95-100 Fast (2-6 h), easy to perform, 
high specificity
Less sensitive than other toxin 
tests
Cytotoxin assay 80-90 99-100 Highly sensitive & specific Costly tissue culture, detects only 
toxin B within 24-48 hours
Latex agglutination 
assay 
58-68 80-96 Fast, inexpensive, easy to 
perform
Low sensitivity to detect toxin in 
stool 
PCR for detection 
toxin genes
92-97 100 Excellent sensitivity and 
specificity compared to all tests 
Done mostly in Research labs 
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(NAATs) are FDA approved for C. difﬁcile testing. 
These assays detect conserved regions of toxin A or 
toxin B genes on the PaLoc of C. difﬁcile [48]. NAAT 
utilizing either polymerase chain reaction (PCR) with 
excellent sensitivity (92%–97%) and specificity 
(100%) or loop-mediated isothermal amplification 
(LAMP), which appear to have similar performances 
is increasingly being used for diagnosis of C. difﬁcile 
infection and healthy carriers who have diarrhea 
from unrelated causes [49]. (Gould et al., 2013). 
Although more expensive than traditional assays, 
these tests have potential for rapid and accurate 
diagnosis [44]. 
For epidemiological purpose, there are various 
methods currently adapted globally to type C. difﬁcile 
isolates, including pulsed-field gel electrophoresis 
(PFGE), PCR ribotyping, toxinotyping based on 
restriction fragment length polymorphism (RFLP), 
restriction endonuclease analysis (REA), multilocus 
variablenumber tandem-repeat analysis (MLVA), 
and multilocus sequence typing (MLST). [50]. 
Treatment of C. difficile clinical 
cases with antibiotics
The most important step in treating CDI is 
immediately discontinuing use of the offending 
antimicrobial drug; and the appropriate antibiotic 
should be treated the patient. Additionally, providing 
appropriate supportive care with rehydration and 
electrolyte replacement as needed, and avoiding the 
use of antiperistaltic agents which may contribute 
to the development of toxic megacolon [12,51]. 
Once the offending antibiotic is discontinued, 
spontaneous resolution of CDAD symptoms will 
be observed in most patients within 2-4 days 
[5,51]. Metronidazole (Flagyl) and oral vancomycin 
have been the main antimicrobial agents used in 
the treatment of CDI. The traditional therapy for 
patients with moderate to severe CDI is either oral 
metronidazole (400 mg 8 hourly) or oral vancomycin 
(125mg 6 hourly) for 10-14 days. Relapse rates of C. 
difﬁcile  have been noted as high as 20% with 
metronidazole and 30% with vancomycin. A study 
has compared oral metronidazole 250 mg four times 
daily to oral vancomycin 250 mg four times daily, 
and the results suggested that oral vancomycin was 
superior for patients severed by severe C. difﬁcile-
associated disease, although the study results did 
not reach statistical significance [12]. Metronidazole 
is currently preferred in guidelines from the Centers 
for Disease Control and Prevention (CDC), Health 
Protection Agency in UK (HPA) (HPA, 2009), the 
Infectious Diseases Society of America (IDSA), and 
the Society for Healthcare Epidemiology of America 
(SHEA), on the basis of low cost and the concern 
that oral vancomycin promotes colonization with 
vancomycin-resistant enterococci (VRE) [5,20]. When 
administered orally, metronidazole is absorbed 
rapidly and almost completely, with only 6–15% of 
the drug excreted in stool. In contrast, vancomycin 
is poorly absorbed, and fecal concentrations after 
oral administration reach high levels [12]. The drug 
of choice for seriously ill patients is oral vancomycin 
(only approved by the US Food and Drug 
Administration (FDA) for CDI), because it has no 
side effect and is not absorbed by the intestine [19]. 
Metronidazole can be associated with severe allergic 
reactions as well as central nervous system toxicity. 
The neurotoxicity associated with metronidazole 
is related to cumulative exposure, and thus occurs 
at a higher rate following prolonged therapy, as 
is often used in cases where repeat C. difﬁcile 
testing remains positive [32]. Treatment does not 
eradicate C. difﬁcile or the toxin from the stool. 
Asymptomatic patients, should not be treated again 
if the stool test was still positive [7]. For first and 
second episodes of diarrhea, metronidazole is still 
recommended, although oral vancomycin should 
be considered when the patient is experiencing 
sepsis associated with  C. difﬁcile infection [20]. 
Newer antimicrobial agents with activity against C. 
difﬁcile have been developed and studied in adults, 
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including fidaxomicin (FDA approved for treatment 
of CDI in adults in 2011), nitazoxanide, and rifaxamin 
but experience with their use in children is limited 
to date [32]. 
Antimicrobial resistance in  
C. difficile 
Drug resistance of C. difﬁcile towards 
metronidazole is still not common, while total 
resistance to vancomycin is not documented over 
the world [52]. In a recent study from Spain, 
a resistance rate for metronidazole (minimum 
inhibitory concentration 32 mg/L) was noted at 
6.3%. It is expected that prolonged exposure to 
metronidazole can be linked to resistance. An earlier 
study from Spain in 2002 noted that 3% of 415 C. 
difﬁcile isolates showed intermediate susceptibilities 
(MIC 4 mcg/mL-16 mcg/mL) to vancomycin [53]. 
Vancomycin contributes to higher selection pressure 
than metronidazole in developing resistance in 
enterococci. With the concerns of high rates of 
relapse, drug resistance and treatment failures, 
other agents are being investigated as alternative 
treatment strategies for CDI[52]. Furthermore, an 
increased rate of C. difﬁcile strains show resistance 
to rifamycins, used for the treatment of relapsing 
CDI has been reported [20,52]. 
Several mechanisms of resistance have been 
identified in  C. difﬁcile, including acquisition of 
genetic elements and alterations of the antibiotic 
target sites. The  C. difﬁcile  genome contains 
mobile genetic elements, many of them involved in 
antibiotic resistance. Transfer of genetic elements 
among C. difﬁcile strains or between C. difﬁcile and 
other bacterial species can occur through different 
mechanisms that facilitate their spread [54]. Antibiotic 
resistance plays an important role in the emergence 
of new C. difﬁcile types. While clindamycin resistance 
was observed in endemic types, new epidemic types 
are associated with resistance to ﬂuoroquinolones 
[55]. Furthermore, resistance to multiple antibiotics 
is a common feature observed in recently emergent 
epidemic isolates. 
A recent Pan-European Longitudinal Surveillance 
has reported there was no evidence of resistance 
to new used fidaxomicin, and reduced susceptibility 
to metronidazole and vancomycin was also scarce. 
Rifampicin, moxiﬂoxacin, and clindamycin resistance 
accounted to 13%, 40%, and 50% of total isolates, 
respectively and were associated with multiple 
ribotypes [56]. The rapid identification of new 
phenotypic and genotypic traits, the implementation 
of effective antimicrobial stewardship and infection 
control programs, use of alternative drugs are all 
important factors to prevent and control the spread 
of resistance and to ensure a successful therapy for 
CDI.
Biotherapy of C. difficile 
clinical cases
Probiotics such as lactobacillus species and 
Saccharomyces boulardii, have shown efficacy 
in reducing the incidence of simple antibiotic-
associated diarrhea, but their efficacy in preventing 
C. difﬁcile infection is not consistent, however, re-
establishment of a healthy intestinal ﬂora is the 
aim of probiotics [20,57]. There are limited data 
to support this treatment approach and there is a 
potential risk of bloodstream infection. Until recently, 
no single study had shown clearly probiotics to be 
effective in the prevention of CDI [5]. 
Clostridiun difficile infection in 
Arab countries
There are few epidemiologic data published on 
C. difﬁcile in Arab countries over the last 15 years 
according the search in 2 most medical famous 
indexing web sites (Pub Med & Scopus). In Jordan, 
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Shehabi et al. [9], performed a study at the Jordan 
University Hospital in 2000 and found a prevalence 
rate of 9.7% C. difﬁcile isolates or its toxin in patient 
stools of all ages with diarrhea by using culture and 
enzyme immunoassay for the detection of C. difﬁcile 
toxin A. A study done in Kuwait by Rotimi et al. in 2002 
[58], reported that the prevalence of hospital acquired 
C. difﬁcile infection/colonization was less than 10%. A 
second study conducted in Kuwait focused on the PCR 
ribotyping of environmental and ICU clinical strains. A 
total of 32 different ribotypes were detected among 
the clinical isolates, and the predominant toxigenic 
ribotypes detected were types 097 and 078, which 
are different from the findings obtained in North 
America and Europe, which exhibited a dominance 
of the 027 ribotype [59]. 
Nasereddin et al. [15], reported an increase in 
CDI rates observed at the Jordan University Hospital 
after abot 8 years of the first study done in the 
same hospital. The study showed a prevalence of 
toxigenic C. difﬁcile isolates was 13.7% among 
adult hospitalized patients, and 73% of the C. 
difﬁcile isolates carried tcdA and/or tcdB toxin genes 
as demonstrated by PCR and in association with 
diarrhea, and all C. difﬁcile isolates were negative for 
binary toxin production. A recent multicenter study 
held in Jordan in 2015 by Wadi et al. [3], detected 
a prevalence rate of 92.4% among hospitalized old 
patients with C. difﬁcile toxin-positive diarrhea-stools 
using a rapid test, which detects fecal C. difﬁcile 
toxins A and B. The adults and older age groups 
accounted for the majority of all positive cases. In 
Saudi Arabia, a study reported a prevalence rate 
of 4.6% of C. difﬁcile among Saudi patients. Stool 
analysis for C. difﬁcile toxins A and B was carried 
out by an enzyme-linked immunosorbent assay 
[60]. In Qatar, Al-Thani et al. [61], recently reported 
a prevalence rate of CDI (7.9%) amongst their 1,532 
hospitalized patients, and their study used glutamate 
dehydrogenase (GDH) lateral ﬂow assay and toxins 
A and B Enzyme Immunoassay (EIA) fordetection of 
C. difﬁcile. A recent Lebanese study demonstrated 
that 30 out 88 (65.2%) of stool samples examined 
of patients admitted to different hospital units at the 
American University Medical Center in Beirut, were 
positive by culture for C. difﬁcile or its toxins (tcdA/
tcdB) or both genes. Their results of toxinotyping 
showed that 2 isolates belonged to toxinotype 0, 4 
to toxinotype XI, 2 to toxinotype XII, 1 to toxinotype 
XVI, 1(A+B-) and twenty (A-B+) designated as 
toxinotype 0-like [62]. The frequency, demography, 
clinical features and outcome of nosocomial CDAD 
in children admitted to Assiut University Children’s 
Hospital,  Egypt, was investigated by a descriptive 
cross-sectional study. Out of 72 examined children, 
17 (23·6%) were diagnosed with CDAD using culture 
for C. difﬁcile and direct toxin detection from stool 
samples by enzyme immuno-assay. Those aged ≤12 
months were the most commonly affected (eight, 
47%). The main cause of admission was respiratory 
disorders (47% of cases) [63].
Lastly, a new not published yet study from Jordan 
(personal communication, 2016), indicated that the 
overall C. difﬁcile colonization rate among Jordanian 
infants aged less than one year was (37/287; 
12.9%). Both toxigenic (54%) and non-toxigenic C. 
difﬁcile strains (46%) were detected. Additionally 
only one isolate (2.7%) was positive for binary 
toxin. All isolates of C. difﬁcile were susceptible 
to vancomycin and metronidazole, while high 
resistance rate to ciproﬂoxacin and low resistance 
rate to erythromycin were detected among the 
isolates. The results of ﬂuoroquinolone resistance 
determining-genes indicated that (40.5%) of the 
isolates carried both gyrA and gyrB.
The presence of toxigenic C. difﬁcile in stools 
of infants without diarrhea, suggests that they 
were asymptomatic carriers of toxigenic strains; 
thus infants may be a potential reservoir to spread 
infection with these trains to other close contact. 
The authors acknowledge that they have no 
conﬂict of interest.
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